Search

Your search keyword '"Tracy, Sean"' showing total 115 results
Start Over Author "Tracy, Sean"
115 results on '"Tracy, Sean"'

1. Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL

Author

Aldoss, Ibrahim, Roloff, Gregory W., Faramand, Rawan, Kopmar, Noam E., Lin, Chenyu, Advani, Anjali S., Dekker, Simone E., Gupta, Vishal K., O'Connor, Timothy E., Jeyakumar, Nikeshan, Muhsen, Ibrahim N., Valtis, Yannis, Zhang, Amy, Miller, Katharine, Sutherland, Katherine, Dykes, Kaitlyn C., Ahmed, Mohamed, Chen, Evan, Zambrano, Hector, Bradshaw, Danielle, Mercadal, Santiago, Schwartz, Marc, Tracy, Sean, Dholaria, Bhagirathbhai, Kubiak, Michal, Mukherjee, Akash, Majhail, Navneet, Battiwalla, Minoo, Mountjoy, Luke, Malik, Shahbaz A., Mathews, John, Shaughnessy, Paul, Logan, Aaron C., Ladha, Abdullah, Stefan, Maryann, Guzowski, Caitlin, Hoeg, Rasmus T., Hilal, Talal, Moore, Jozal, Connor, Matthew, O'Dwyer, Kristen M., Hill, LaQuisa C., Tsai, Stephanie B., Sasine, Joshua, Solh, Melhem M., Lee, Catherine J., Kota, Vamsi K., Koura, Divya, Veeraputhiran, Muthu, Blunk, Betsy, Oliai, Caspian, Leonard, Jessica T., Frey, Noelle V., Park, Jae H., Luskin, Marlise R., Bachanova, Veronika, Galal, Ahmed, Bishop, Michael R., Stock, Wendy, Cassaday, Ryan D., Pullarkat, Vinod, Shah, Bijal D., and Muffly, Lori S.

Published
2024
Full Text
View/download PDF

3. Patients with TP53 -Mutated Acute Myeloid Leukemia Receiving Intensive Induction Therapy Have Superior Outcomes Due to a Higher Rate of Salvage Therapy: A Single Institution, Retrospective Study.

Author

Sumransub, Nuttavut, Steinwand, Gabriel K., Cordner, Keith, Lee, Yoonkyu, Cao, Qing, Allred, Jeremy, Bachanova, Veronika, Juckett, Mark, Eckfeldt, Craig, Maakaron, Joseph E., Tracy, Sean I., Ramesh, Vidhyalakshmi, Nelson, Andrew C., Yohe, Sophia, and Sachs, Zohar

Subjects
THERAPEUTIC use of antineoplastic agents, RESEARCH funding, SALVAGE therapy, PATHOLOGIC complete response, TREATMENT effectiveness, RETROSPECTIVE studies, CANCER patients, DISEASE remission, DESCRIPTIVE statistics, TUMOR suppressor genes, ONCOGENES, MEDICAL records, ACQUISITION of data, GENETIC mutation, INDUCTION chemotherapy, OVERALL survival, EVALUATION
Abstract

Simple Summary: Mutations in the gene, TP53, define the most treatment-resistant subtype of acute myeloid leukemia (AML). Patients with TP53-mutated AML invariably develop disease recurrence after treatment, leading to short survival times. Previous studies have shown that less than 10% of these patients survive beyond 2 years after diagnosis. Moreover, the best treatment approach for these patients is still unclear. Our study is the first to analyze therapy results beyond first-line treatment, highlighting the importance of therapy sequencing in managing these patients. We found that sequential treatment with intensive chemotherapy followed by a less-intensive regimen achieved the highest remission rate of over 65%. Eligible patients should then receive blood stem cell transplantation from a donor, which significantly improves long-term survival. Our study provides crucial data to guide management and optimize therapy sequencing for better survival in this treatment-resistant disease. Background: TP53 mutations (TP53m) define the most treatment-refractory acute myeloid leukemia (AML) subtype. Optimal treatment approaches have not been established in this setting. We reviewed our institutional experience to identify therapy sequencing, treatment response, and survival patterns in these patients. Methods: This study was a single-center, retrospective cohort analysis. Results: Our cohort includes 86 TP53m and 337 TP53 wild-type (TP53wt) adult AML patients. TP53m AML patients presented with lower bone marrow and peripheral blasts; none presented with hyperleukocytosis. Patients who received intensive treatment up front demonstrated superior overall survival (OS) over those receiving first-line non-intensive therapy (2-year OS 22% versus 7%; p = 0.02). However, the complete remission (CR) rates among the first-line intensive and non-intensive therapy groups were comparable (21.9% and 29.4%, respectively, p = 0.49). The improved OS is therefore attributed to superior cumulative CR in the intensive group. First-line intensively treated patients were more likely to receive and respond to salvage, leading to a cumulative CR rate of 65.7% (versus 29.4%, p = 0.003). Achieving CR at any point is strongly associated with superior survival outcomes with 2-year OS of 31% versus 0% for those not achieving CR ever (p < 0.01). Conclusions: We find that TP53m AML rarely presents with oncological emergencies, suggesting that clinical trial enrollment is feasible in this group. Additionally, in our cohort, intensive induction therapies lead to superior survival outcomes attributed to successful salvage therapy. These data suggest that strategic therapy sequencing and salvage therapy may be important in optimizing outcomes for TP53m AML patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Author

Lin, Chenyu, primary, Tsai, Dr. Stephanie B., additional, Roloff, Gregory, additional, Zhang, Amy, additional, Aldoss, Ibrahim, additional, Kopmar, Noam E., additional, Dekker, Simone E., additional, Jeyakumar, Nikeshan, additional, Gupta, Vishal, additional, O'Connor, Timothy E, additional, Dykes, Kaitlyn C, additional, Ahmed, Mohamed, additional, Dholaria, Dr. Bhagirathbhai, additional, Zambrano, Hector, additional, Bradshaw, Danielle, additional, Logan, Aaron C., additional, Tracy, Sean, additional, Kubiak, Michal, additional, Solh, Melhem M, additional, Mercadal, Santiago, additional, Schwartz, Marc, additional, Mukherjee, Akash, additional, Battiwalla, Minoo, additional, Shaughnessy, Paul J., additional, Majhail, Navneet S., additional, Mountjoy, Luke, additional, Malik, Shahbaz, additional, Mathews, John, additional, Ladha, Dr. Abdullah, additional, Advani, Anjali S., additional, Stefan, Maryann, additional, Guzowski, Caitlin, additional, Hoeg, Rasmus T, additional, Hilal, Talal, additional, Moore, Jozal W., additional, O'Dwyer, Kristen M, additional, Sasine, Joshua P, additional, Lee, Catherine J, additional, Kota, Vamsi, additional, Koura, Divya, additional, Veeraputhiran, Muthu, additional, Blunk, Betsy, additional, Leonard, Jessica T., additional, Oliai, Caspian, additional, Bachanova, Veronika, additional, Stock, Wendy, additional, Pullarkat, Vinod, additional, Cassaday, Ryan D., additional, Miller, Katharine, additional, Muffly, Lori S, additional, Galal, Ahmed, additional, Shah, Bijal D., additional, and Faramand, Rawan G, additional

Published
2024
Full Text
View/download PDF

5. Real World Outcomes for AYA Patients with Relapsed/Refractory B-Cell ALL Receiving CD19-Directed CAR T-Cell Therapy

Author

Lust, Hannah, primary, Roloff, Gregory, additional, Schultz, Liora Michal, additional, Muffly, Lori S, additional, Krugman, Jessica, additional, Aldoss, Ibrahim, additional, Kwon, Soyang, additional, Kubiak, Michal, additional, Lee, Catherine J., additional, Cassaday, Ryan D., additional, Shah, Bijal D., additional, Baggott, Christina, additional, Kopmar, Noam E., additional, Bradshaw, Danielle, additional, Schwartz, Marc, additional, Tracy, Sean, additional, Mukherjee, Akash, additional, Ladha, Abdullah, additional, Yaghmour, George, additional, Advani, Anjali S., additional, Stefan, Maryann, additional, Kota, Vamsi, additional, Veeraputhiran, Muthu, additional, Stock, Wendy, additional, Rossoff, Jenna, additional, Qayed, Muna, additional, Talano, Julie A, additional, Curran, Kevin J., additional, Phillips, Christine L, additional, Karras, Nicole, additional, Fabrizio, Vanessa A., additional, Baumeister, Susanne H.C., additional, Cooper, Stacy, additional, Hermiston, Michelle, additional, Satwani, Prakash, additional, Macmillan, Margaret, additional, John, Samuel, additional, and Faramand, Rawan G, additional

Published
2024
Full Text
View/download PDF

6. The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Author

O'Connor, Timothy E, primary, Lin, Chenyu, additional, Roloff, Gregory, additional, Zhang, Amy, additional, Aldoss, Ibrahim, additional, Faramand, Rawan G, additional, Kopmar, Noam E., additional, Dykes, Kaitlyn C, additional, Jeyakumar, Nikeshan, additional, Dekker, Simone E., additional, Gupta, Vishal, additional, Ahmed, Mohamed, additional, Logan, Aaron C., additional, Zambrano, Hector, additional, Bradshaw, Danielle, additional, Mercadal, Santiago, additional, Schwartz, Marc, additional, Tracy, Sean, additional, Kubiak, Michal, additional, Mukherjee, Akash, additional, Majhail, Navneet S., additional, Battiwalla, Minoo, additional, Mountjoy, Luke, additional, Malik, Shahbaz, additional, Mathews, John, additional, Shaughnessy, Paul J., additional, Ladha, Abdullah, additional, Advani, Anjali S., additional, Stefan, Maryann, additional, Guzowski, Caitlin, additional, Hoeg, Rasmus T, additional, Hilal, Talal, additional, Moore, Jozal W., additional, O'Dwyer, Kristen M, additional, Sasine, Joshua P, additional, Solh, Melhem M, additional, Lee, Catherine J., additional, Kota, Vamsi, additional, Koura, Divya, additional, Veeraputhiran, Muthu, additional, Blunk, Betsy, additional, Leonard, Jessica T., additional, Oliai, Caspian, additional, Bachanova, Veronika, additional, Stock, Wendy, additional, Pullarkat, Vinod, additional, Cassaday, Ryan D., additional, Shah, Bijal D., additional, Miller, Katharine, additional, Muffly, Lori S, additional, Galal, Ahmed, additional, Tsai, Dr. Stephanie B., additional, and Dholaria, Dr. Bhagirathbhai, additional

Published
2024
Full Text
View/download PDF

12. Ph‐like gene alterations and complex chromosomal abnormalities are frequent in patients with acute lymphoblastic leukemia experiencing relapse after allogeneic hematopoietic cell transplantation

Author

Tracy, Sean I., primary, Cao, Qing, additional, Bachan, Ben, additional, Meredith, Matthew, additional, Oseth, LeAnn, additional, Weisdorf, Daniel, additional, Brunstein, Claudio, additional, Hirsch, Betsy, additional, and Bachanova, Veronika, additional

Published
2022
Full Text
View/download PDF

19. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

Author

Engelman, Jeffrey A., Mukohara, Toru, Zejnullahu, Kreshnik, Lifshits, Eugene, Borras, Ana M., Gale, Christopher-Michael, Naumov, George N., Yeap, Beow Y., Jarrell, Emily, Sun, Jason, Tracy, Sean, Zhao, Xiaojun, Heymach, John V., Johnson, Bruce E., Cantley, Lewis C., and Janne, Pasi A.

Subjects
Endothelial growth factors -- Research, Adenocarcinoma -- Drug therapy, Gefitinib -- Dosage and administration, Gefitinib -- Complications and side effects
Abstract

EGFR is frequently mutated and amplified in lung adenocarcinomas sensitive to EGFR inhibitors gefitinib and erlotinib. A secondary mutation, T790M, has been associated with acquired resistance but has not been [...]

Published
2006

24. The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non‐follicular indolent B‐cell lymphomas

Author

Tracy, Sean I., primary, Larson, Melissa C., additional, Feldman, Andrew L., additional, Maurer, Matthew J., additional, Novak, Anne J., additional, Slager, Susan L., additional, Villasboas, Jose C., additional, Allmer, Cristine, additional, Habermann, Thomas M., additional, Farooq, Umar, additional, Syrbu, Sergei, additional, Cerhan, James R., additional, and Link, Brian K., additional

Published
2019
Full Text
View/download PDF

26. Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression

Author

Tracy, Sean I., primary, Habermann, Thomas M., additional, Feldman, Andrew L., additional, Maurer, Matthew J., additional, Dogan, Ahmet, additional, Perepu, Usha S., additional, Syrbu, Sergei, additional, Ansell, Stephen M., additional, Thompson, Carrie A., additional, Weiner, George J., additional, Nowakowski, Grzegorz S., additional, Allmer, Cristine, additional, Slager, Susan L., additional, Witzig, Thomas E., additional, Cerhan, James R., additional, and Link, Brian K., additional

Published
2017
Full Text
View/download PDF

27. CryENGINE 3 Game Development:Beginner's Guide

Author

Tracy, Sean, Reindell, Paul, Tracy, Sean, Tracy, Sean, Reindell, Paul, and Tracy, Sean

Abstract

A step by step beginner's tutorial to creating AAA style games with the complete game creation tool, CryENGINE 3,This book is written with the beginner and casual developer in mind. The freely available version of the CryENGINE® 3 is used for all examples in this book.

Published
2012

28. Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma

Author

Tracy, Sean I., primary, Maurer, Matthew J, additional, Witzig, Thomas E., additional, Drake, Matthew T., additional, Ansell, Stephen, additional, Nowakowski, Grzegorz S., additional, Inwards, David James, additional, Thompson, Carrie A, additional, Johnston, Patrick B., additional, Micallef, Ivana, additional, Allmer, Cristine, additional, Macon, William R., additional, Weiner, George J, additional, Slager, Susan L., additional, Habermann, Thomas M., additional, Link, Brian K, additional, and Cerhan, James R, additional

Published
2016
Full Text
View/download PDF

29. No Association of EBV or Immunosuppression Status with Outcomes in US Patients with Diffuse Large B-Cell Lymphoma Treated in the Immunochemotherapy Era

Author

Tracy, Sean I., primary, Habermann, Thomas M., additional, Feldman, Andrew L, additional, Maurer, Matthew J, additional, Dogan, Ahmet, additional, Perepu, Usha S, additional, Syrbu, Sergei, additional, Ansell, Stephen, additional, Thompson, Carrie A, additional, Weiner, George J, additional, Allmer, Cristine, additional, Slager, Susan L., additional, Witzig, Thomas E., additional, Cerhan, James R, additional, and Link, Brian K, additional

Published
2016
Full Text
View/download PDF

30. Reconciling comprehensive liberalism and Islam

Author

Tracy, Sean Michael, Thorpe, Lucas, Westphal, Kenneth Robert, Nomer, Nedim Nami, and Felsefe Anabilim Dalı

Subjects
Philosophy, Felsefe, Inclusiveness, Siyasal Bilimler, Kant, Immanuel, Ontology, Political Science, Liberalism, Islam
Abstract

Kok-Chor Tan'ın tanımladığı ve Immanuel Kant tarafından da onanan bireysel özerklik ilkesine dayanan kapsamlı liberalism kavramının, İslam'ın kök ilkeleri ile ne ölçüde uyumlu olduğunu belirlemeyi amaçlıyorum. Diğer yandan, Batı ve İslam dünya görüşü arasında farklı ontolojik-epistemolojik varsayımların tamamen uyumsuz sosyo-politik sistemler olduğunu belirten Ahmet Davutoğlu'nun argümanlarından bahsediyorum. Bu görüşe alternative olarak, Davutoğlu'nun İslam'ın değişmez kökten ilkeleri olarak bahsettiğ bazı ontolojik varsayımların, tamamlayıcı liberalizmin bireysel özerklik ilkesiyle uyumlu olduğunu savunuyorum. Bunu yaparken de nesnesel islam doğal kanun teorisini (NLT) kullanmayı amaçlıyorum. Bu kanunlar İslamın ontolojik varsayımlarını korumanın yanında, Immanuel Kant'ın felsefesinden alınan kapsayıcı liberalism kavramıyla axiolojik, epistemolojik ve sosyopolitik olarak uyumlu olduğunu göstermektedir. I intend in this paper to determine the extent to which particular fundamental principles of Islam are compatible with some form of comprehensive liberalism based upon the primary value of individual autonomy as described by Kok-Chor Tan and justified by Immanuel Kant. On the other hand, I utilize Ahmet Davutoğlu's arguments that differing ontologico-epistemological assumptions between the Western and Islamic Weltanschauungs determine altogether alternative and incompatible axiological and socio-political systems between the two. Instead, I argue that the particular ontological assumptions Davutoğlu claims are fundamental and universal to Islam are compatible with comprehensive liberalism's value of individual autonomy. I attempt to demonstrate this by utilizing a particular tradition of Islamic philosophy Anver Emon calls Hard Islamic natural law theory (NLT). I argue that Hard Islamic NLTs not only preserve the fundamental ontological assumptions of Islam, but also, that they are compatible with the epistemological, axiological, and socio-political domains of a version of comprehensive liberalism that can be derived from the philosophy of Immanuel Kant. Since Hard Islamic NLTs maintain this particular fundamental Islamic ontology while also adopting these elements of the so-called Western paradigm, I conclude that they may be capable of reconciling comprehensive liberalism and Islam. 71

Published
2015

31. CryENGINE 3 Cookbook

Author

Tracy, Sean, Tracy, Sean, Tracy, Dan, Tracy, Sean, Tracy, Sean, and Tracy, Dan

Abstract

Written in a cookbook style, this book offers solutions using a recipe based approach. Each recipe contains step-by-step instructions followed by an analysis of what was done in each task and other useful information. The cookbook approach means you can dive into whatever recipes you want in no particular order. The CryENGINE3 Cookbook is written to be accessible to all developers currently using the CryENGINE3. It also explores the depth and power of the CryENGINE3 and is a useful guide to follow when becoming familiar with this award winning middle-ware game engine. This book is written with the casual and professional developer in mind. Fundamental knowledge of some Digital Content Creation Tools, like Photoshop and 3d Studio Max is required. The Software Development Kit version of the CryENGINE is used for all examples, so the reader should have a version of the development kit to follow the recipes contained in this book.

Published
2011

32. Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

Author

Lin, Chenyu, Tsai, Stephanie B., Roloff, Gregory W, Zhang, Amy, Aldoss, Ibrahim, Kopmar, Noam E., Dekker, Simone E., Jeyakumar, Nikeshan, Gupta, Vishal K, O'Connor, Timothy E, Dykes, Kaitlyn C, Ahmed, Mohamed, Dholaria, Bhagirathbhai, Zambrano, Hector, Bradshaw, Danielle, Logan, Aaron C., Tracy, Sean, Kubiak, Michal, Solh, Melhem M., Mercadal, Santiago, Schwartz, Marc, Mukherjee, Akash, Battiwalla, Minoo, Shaughnessy, Paul, Majhail, Navneet, Mountjoy, Luke, Malik, Shahbaz A., Mathews, John, Ladha, Abdullah, Advani, Anjali S., Stefan, Maryann, Guzowski, Caitlin, Hoeg, Rasmus T., Hilal, Talal, Moore, Jozal, O'Dwyer, Kristen M., Sasine, Joshua, Lee, Catherine J., Kota, Vamsi K., Koura, Divya, Veeraputhiran, Muthu, Blunk, Betsy, Leonard, Jessica T., Oliai, Caspian H., Bachanova, Veronika, Stock, Wendy, Pullarkat, Vinod, Cassaday, Ryan D, Miller, Katharine, Muffly, Lori S., Galal, Ahmed, Shah, Bijal D., and Faramand, Rawan

Abstract

Introduction:

Published
2023
Full Text
View/download PDF

33. The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Author

O'Connor, Timothy E, Lin, Chenyu, Roloff, Gregory W, Zhang, Amy, Aldoss, Ibrahim, Faramand, Rawan, Kopmar, Noam E., Dykes, Kaitlyn C, Jeyakumar, Nikeshan, Dekker, Simone E., Gupta, Vishal K, Ahmed, Mohamed, Logan, Aaron C., Zambrano, Hector, Bradshaw, Danielle, Mercadal, Santiago, Schwartz, Marc, Tracy, Sean, Kubiak, Michal, Mukherjee, Akash, Majhail, Navneet, Battiwalla, Minoo, Mountjoy, Luke, Malik, Shabaz, Mathews, John, Shaughnessy, Paul, Ladha, Abdullah, Yaghmour, George, Advani, Anjali S., Stefan, Maryann, Guzowski, Caitlin, Hoeg, Rasmus T., Hilal, Talal, Moore, Jozal, Sasine, Joshua, Solh, Melhem M., Lee, Catherine J., Kota, Vamsi K., Koura, Divya, Veeraputhiran, Muthu, Blunk, Betsy, Leonard, Jessica T., Oliai, Caspian H., Bachanova, Veronika, Stock, Wendy, Cassaday, Ryan D, Shah, Bijal D., Miller, Katharine, Muffly, Lori S., Galal, Ahmed, Tsai, Stephanie B., and Dholaria, Bhagirathbhai

Abstract

Background

Published
2023
Full Text
View/download PDF

34. A Specialized CD4+ T-Cell Subset Protects Residual Leukemic Cells from Immune Surveillance, Enabling Relapse

Author

Tracy, Sean, Venkatesh, Hrishi, Knutson, Todd P., Qiu, Yinjie, and Farrar, Michael A.

Abstract

Outcomes for patients with acute lymphoblastic leukemia (ALL) continue to improve in the era of immune- therapies. Despite this, measurable residual disease (MRD) frequently persists after frontline treatment, necessitating allogeneic hematopoietic stem cell transplantation or prolonged chemotherapy lasting multiple years. Relapse remains common and is associated with long-term survival rates of <25%. This emphasizes the need for research into fundamental mechanisms that enable the persistence of leukemic blasts.

Published
2023
Full Text
View/download PDF

35. Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from a Multicenter Real-World Outcomes Study

Author

Kopmar, Noam E., Gooley, Ted, Roloff, Gregory W, Aldoss, Ibrahim, Lin, Chenyu, Dekker, Simone E., Gupta, Vishal K, Jeyakumar, Nikeshan, O'connor, Timothy, Dykes, Kaitlyn C, Ahmed, Mohamed, Zambrano, Hector, Bradshaw, Danielle, Mercadal, Santiago, Schwartz, Marc, Tracy, Sean, Dholaria, Bhagirathbhai, Kubiak, Michal, Mukherjee, Akash, Majhail, Navneet, Battiwalla, Minoo, Mountjoy, Luke, Malik, Shabaz, Shaughnessy, Paul, Mathews, John, Logan, Aaron C., Ladha, Abdullah, Yaghmour, George, Advani, Anjali S., Stefan, Maryann, Guzowski, Caitlin, Hoeg, Rasmus T., Hilal, Talal, Moore, Jozal, O'Dwyer, Kristen M., Tsai, Stephanie B., Sasine, Joshua, Solh, Melhem M., Lee, Catherine J., Kota, Vamsi K., Koura, Divya, Veeraputhiran, Muthu, Blunk, Betsy, Leonard, Jessica T., Oliai, Caspian H., Bachanova, Veronika, Stock, Wendy, Galal, Ahmed, Pullarkat, Vinod, Shah, Bijal D., Faramand, Rawan, Muffly, Lori S., and Cassaday, Ryan D

Abstract

Introduction:

Published
2023
Full Text
View/download PDF

36. The Impact of Inotuzumab Ozogamicin (InO) Treatment on Brexucabtagene Autoleucel (Brexu-cel) Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Author

Aldoss, Ibrahim, Roloff, Gregory W, Advani, Anjali S., Kopmar, Noam E., Lin, Chenyu, Dekker, Simone E., Gupta, Vishal K, Jeyakumar, Nikeshan, O'Connor, Timothy E, Zhang, Amy, Miller, Katharine, Dykes, Kaitlyn C, Ahmed, Mohamed, Zambrano, Hector, Bradshaw, Danielle, Mercadal, Santiago, Schwartz, Marc, Tracy, Sean, Dholaria, Bhagirathbhai, Kubiak, Michal, Mukherjee, Akash, Majhail, Navneet, Battiwalla, Minoo, Mountjoy, Luke, Malik, Shahbaz A., Mathews, John, Shaughnessy, Paul, Logan, Aaron C., Ladha, Abdullah, Yaghmour, George, Stefan, Maryann, Guzowski, Caitlin, Hoeg, Rasmus T., Hilal, Talal, Moore, Jozal, O'Dwyer, Kristen M., Tsai, Stephanie B., Sasine, Joshua, Solh, Melhem M., Lee, Catherine J., Kota, Vamsi K., Koura, Divya, Veeraputhiran, Muthu, Blunk, Betsy, Leonard, Jessica T., Oliai, Caspian H., Bachanova, Veronika, Stock, Wendy, Galal, Ahmed, Pullarkat, Vinod, Cassaday, Ryan D, Shah, Bijal D., Faramand, Rawan, and Muffly, Lori S.

Abstract

Cellular Immunotherapies: Late Phase and Commercially Available Therapies

Published
2023
Full Text
View/download PDF

39. Association of vitamin D insufficiency with inferior prognosis in follicular lymphoma.

Author

Tracy, Sean I., primary, Maurer, Matthew John, additional, Witzig, Thomas E., additional, Drake, Matthew, additional, Ansell, Stephen Maxted, additional, Nowakowski, Grzegorz S., additional, Thompson, Carrie A., additional, Inwards, David James, additional, Johnston, Patrick B., additional, Micallef, Ivana N. M., additional, Allmer, Cristine, additional, Macon, William R, additional, Weiner, George J., additional, Slager, Susan L., additional, Habermann, Thomas Matthew, additional, Link, Brian K., additional, and Cerhan, James Robert, additional

Published
2016
Full Text
View/download PDF

40. Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.

Author

Roloff, Gregory, Faramand, Rawan, Aldoss, Ibrahim, Kopmar, Noam Edward, Schwartz, Marc, Dekker, Simone E., Lin, Chenyu, Tracy, Sean, Mercadal Vilchez, Santiago, Dykes, Kaitlyn, O'Connor, Timothy, Ahmed, Mohamed Amin, Gupta, Vishal K, Ladha, Abdullah, Tsai, Stephanie, Leonard, Jessica Taft, Galal, Ahmed, Cassaday, Ryan Daniel, Shah, Bijal D., and Muffly, Lori S.

Published
2023
Full Text
View/download PDF

41. CryENGINE 3 Game Development:Beginner's Guide

Author

Reindell, Paul, Reindell, Paul, Tracy, Sean, Reindell, Paul, Reindell, Paul, and Tracy, Sean

Abstract

A step by step beginner's tutorial to creating AAA style games with the complete game creation tool, CryENGINE 3,This book is written with the beginner and casual developer in mind. The freely available version of the CryENGINE® 3 is used for all examples in this book.

Published
2012

42. CryENGINE 3 Cookbook

Author

Tracy, Dan, Tracy, Sean, Tracy, Dan, Tracy, Dan, Tracy, Sean, and Tracy, Dan

Abstract

Written in a cookbook style, this book offers solutions using a recipe based approach. Each recipe contains step-by-step instructions followed by an analysis of what was done in each task and other useful information. The cookbook approach means you can dive into whatever recipes you want in no particular order. The CryENGINE3 Cookbook is written to be accessible to all developers currently using the CryENGINE3. It also explores the depth and power of the CryENGINE3 and is a useful guide to follow when becoming familiar with this award winning middle-ware game engine. This book is written with the casual and professional developer in mind. Fundamental knowledge of some Digital Content Creation Tools, like Photoshop and 3d Studio Max is required. The Software Development Kit version of the CryENGINE is used for all examples, so the reader should have a version of the development kit to follow the recipes contained in this book.

Published
2011

47. EGFRMutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Author

Paez, J. Guillermo, primary, Jänne, Pasi A., additional, Lee, Jeffrey C., additional, Tracy, Sean, additional, Greulich, Heidi, additional, Gabriel, Stacey, additional, Herman, Paula, additional, Kaye, Frederic J., additional, Lindeman, Neal, additional, Boggon, Titus J., additional, Naoki, Katsuhiko, additional, Sasaki, Hidefumi, additional, Fujii, Yoshitaka, additional, Eck, Michael J., additional, Sellers, William R., additional, Johnson, Bruce E., additional, and Meyerson, Matthew, additional

Published
2004
Full Text
View/download PDF

48. Combining nilotinib and PD-L1 blockade reverses CD4+T-cell dysfunction and prevents relapse in acute B-cell leukemia

Author

Tracy, Sean I., Venkatesh, Hrishi, Hekim, Can, Heltemes-Harris, Lynn M., Knutson, Todd P., Bachanova, Veronika, and Farrar, Michael A.

Abstract

Patients with acute lymphoblastic leukemia have experienced significantly improved outcomes due to the advent of chimeric antigen receptor T-cells and bispecific T-cell engagers, although a proportion of patients still relapse despite these advances. T-cell exhaustion has been recently suggested to be an important driver of relapse in these patients. Indeed, phenotypic exhaustion of CD4+T-cells is predictive of relapse and poor overall survival in B-ALL. Thus, therapies that counter T-cell exhaustion, such as immune checkpoint blockade, may improve leukemia immunosurveillance and prevent relapse. Here, we used a murine model of Ph+B-ALL as well as human bone marrow biopsy samples to assess the fundamental nature of CD4+T-cell exhaustion and the preclinical therapeutic potential for combining anti-PD-L1 based checkpoint blockade with tyrosine kinase inhibitors targeting the BCR-ABL oncoprotein. scRNA-seq analysis revealed that B-ALL induces a unique subset of CD4+T-cells with both cytotoxic and helper functions. Combination treatment with the tyrosine kinase inhibitor nilotinib and anti-PD-L1 dramatically improves long-term survival of leukemic mice. Depletion of CD4+T-cells prior to therapy completely abrogates the survival benefit, implicating CD4+T-cells as key drivers of the protective anti-leukemia immune response. Indeed, treatment with anti-PD-L1 leads to clonal expansion of leukemia-specific CD4+T-cells with the afore-mentioned helper/cytotoxic phenotype, as well as reduced expression of exhaustion markers. These findings support efforts to utilize PD1/PD-L1 checkpoint blockade in clinical trials and highlight the importance of CD4+T-cell dysfunction in limiting the endogenous anti-leukemia response.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results